/4536.T

4536.T Stock - Santen Pharmaceutical Co., Ltd.

Q: What is the analyst price target for 4536.T?

Analyst price target information is not currently available for 4536.T.

Q: What is 4536.T's market cap?

Market capitalization information is not currently available for 4536.T.

Healthcare|Drug Manufacturers - General|JPX

$1636.50-0.76%

$12.50 (-0.76%) • Dec 24

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1800.15

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for 4536.T

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.26

52W High$1722.00

52W Low$1310.50

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$300.00B	$301.96B	$279.04B	$266.26B	$249.60B
Gross Profit	$171.03B	$178.71B	$166.09B	$156.59B	$151.38B
Gross Margin	57.0%	59.2%	59.5%	58.8%	60.6%
Operating Income	$56.23B	$51.90B	$32.02B	$35.89B	$37.07B
Net Income	$36.25B	$26.64B	$-14,948,000,000	$27.22B	$9.31B
Net Margin	12.1%	8.8%	-5.4%	10.2%	3.7%
EPS	$103.98	$72.62	$-38.60	$68.07	$23.30

Company Overview

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Visit Website

Earnings History & Surprises

4536.T

Beat Rate

78%

Last 18 quarters

Avg Surprise

-34.5%

EPS vs Estimate

Beats / Misses

14/4

Last 12 quarters

Latest EPS

$23.70

Q4 2025

EPS Surprise History

Q1 24

+32.8%

$20.20vs$15.21

Q2 24

-97.6%

$0.33vs$13.64

Q3 24

+33.5%

$29.59vs$22.17

Q4 24

+7.4%

$23.29vs$21.69

Q1 25

+4.5%

$25.33vs$24.24

Q2 25

+61.1%

$25.79vs$16.01

Q3 25

-27.7%

$17.28vs$23.90

Q4 25

+13.5%

$23.70vs$20.89

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 11, 2026	—	—	—	—
Q1 2026	Feb 5, 2026	—	—	—	—
Q4 2025	Nov 6, 2025	$20.89	$23.70	+13.5%	✓ BEAT
Q3 2025	Aug 7, 2025	$23.90	$17.28	-27.7%	✗ MISS
Q2 2025	May 13, 2025	$16.01	$25.79	+61.1%	✓ BEAT
Q1 2025	Feb 6, 2025	$24.24	$25.33	+4.5%	✓ BEAT
Q4 2024	Nov 7, 2024	$21.69	$23.29	+7.4%	✓ BEAT
Q3 2024	Aug 6, 2024	$22.17	$29.59	+33.5%	✓ BEAT
Q2 2024	May 9, 2024	$13.64	$0.33	-97.6%	✗ MISS
Q1 2024	Feb 8, 2024	$15.21	$20.20	+32.8%	✓ BEAT
Q4 2023	Nov 7, 2023	$13.19	$24.13	+82.9%	✓ BEAT
Q3 2023	Aug 3, 2023	$17.19	$27.93	+62.5%	✓ BEAT
Q2 2023	May 11, 2023	$2.33	$2.96	+27.0%	✓ BEAT
Q1 2023	Feb 7, 2023	$14.00	$14.92	+6.6%	✓ BEAT
Q4 2022	Nov 8, 2022	$9.66	$-72.84	-854.0%	✗ MISS
Q3 2022	Aug 4, 2022	$16.52	$19.55	+18.3%	✓ BEAT
Q2 2022	May 10, 2022	$19.61	$19.68	+0.4%	✓ BEAT
Q1 2022	Feb 10, 2022	$14.75	$12.60	-14.6%	✗ MISS
Q4 2021	Nov 8, 2021	$15.90	$17.32	+8.9%	✓ BEAT
Q3 2021	Aug 6, 2021	$16.25	$18.47	+13.7%	✓ BEAT

Frequently Asked Questions about 4536.T

What is 4536.T's current stock price?

Santen Pharmaceutical Co., Ltd. (4536.T) is currently trading at $1636.50 per share. The stock has moved -0.76% today.

What is the analyst price target for 4536.T?

No analyst price targets are currently available for this stock.

What sector is Santen Pharmaceutical Co., Ltd. in?

Santen Pharmaceutical Co., Ltd. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the JPX exchange.

What is 4536.T's market cap?

Santen Pharmaceutical Co., Ltd. has a market capitalization of $553.12 billion, making it a mega-cap company.

Does 4536.T pay dividends?

No, Santen Pharmaceutical Co., Ltd. does not currently pay a dividend to shareholders.